Five month study follow up - SCENESSE in vitiligo (CUV102)
Filed with ASX ·
6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- US orphan-drug designation in Hailey-Hailey Disease
- Phase II vitiligo study commences in Singapore
- Media Release- Clinuvel successful in US Phase III trial
- EMA review of SCENESSE extended to mid-2014
- Clinuvel placement
Later from Clinuvel Pharmaceuticals
- Appendix 4D - Half Yearly Report
- Appendix 4E - Preliminary Final Report
- Clinuvel announces positive results of Phase II US study
- Clinuvel commences US Phase III trial of SCENESSE
- Clinuvel completes pre-clinical program for SCENESSE
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals